Space-expanding skull shield used during decompressive surgery for severe stroke
Official title: A Space-expanding Shield in Decompressive Hemicraniectomy for Stroke - a Randomized-controlled Multicenter Phase III Trial
Run by Insel Gruppe AG, University Hospital Bern · NCT06638385 · Data updated 2026-11-12
This trial will try placing a custom space‑expanding skull shield at the time of decompressive hemicraniectomy to let the brain swell safely and reduce the need for a second skull-replacement surgery in adults with malignant middle cerebral artery stroke.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 6 sites (Aarau and 5 other locations) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | December 31, 2029 |
| Study ends | June 30, 2030 |
| Registry record updated | July 9, 2025 |
| Trial ID | NCT06638385 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 to under 70 with malignant middle cerebral artery infarction who meet European guidelines for decompressive hemicraniectomy and can provide consent via next of kin and an independent physician are eligible.
✕Probably not a fit
Patients with an immediate hyperacute need for decompression, known allergy to PMMA or gentamicin, pregnancy, prior decompressive or cranioplasty surgery, active cranial or pulmonary infection, or intrinsic coagulopathy are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Malignant middle cerebral artery infarction can cause life-threatening brain swelling that is usually managed by removing a portion of the skull (decompressive hemicraniectomy) followed months later by a second operation to replace the bone (cranioplasty). This study tests a single-stage approach in which a polymethyl‑methacrylate (PMMA) shield is molded and implanted immediately after skull removal to allow swelling while protecting the brain. Participants will receive either decompressive hemicraniectomy plus the space‑expanding shield or decompressive hemicraniectomy followed by standard cranioplasty and will be followed for six months. Enrollment is planned at three Swiss neurosurgery centers between 2025 and 2029.
Why it matters
Potential benefit: If successful, the single-stage shield approach could eliminate a second surgery and reduce complications such as brain exposure, bone resorption, and the syndrome of the trephined.
How similar studies have gone: A prior prospective cohort suggested the intraoperatively molded shield may prevent several cranioplasty-related complications, but randomized and larger comparative data are limited and the single-stage approach remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with malignant infarction of the middle cerebral artery identified by MRI including diffusion-weighted imaging or CT including perfusion imaging - fulfilling the European guidelines for decompressive hemicraniectomy (DCE) for stroke * ≥ 18 and \< 70 years of age * Availability of consent from a next of kin and from the patient represented by an independent physician Exclusion Criteria: * Hyperacute need for DCE due to rapid neurological decline * Contraindications to the use of polymethyl-methacrylate (PMMA), e.g., known hypersensitivity, allergy * Known gentamicin allergy * Pregnancy and active breast-feeding * Patients with a former history of DCE and/or CP * Active pulmonary or cranial infection * Known coagulopathy independent of medication
Where it's running
-
Kantonsspital Aarau
Aarau, Switzerland Recruiting -
Universitätsspital Basel
Basel, Switzerland Recruiting -
Inselspital Bern, Department of Neurosurgery
Bern, Switzerland Recruiting -
Luzerner Kantonsspital
Lucerne, Switzerland Recruiting -
Ente Ospedaliero Cantonale
Lugano, Switzerland Recruiting -
Kantonsspital St.Gallen
Sankt Gallen, Switzerland Recruiting
Study contacts
- Principal investigator: Schucht Philippe, MD — Inselspital Bern, Department of Neurosurgery
- Study coordinator: Philippe Schucht, MD
- Email: philippe.schucht@insel.ch
- Phone: +41316322409
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Deep phenotyping to explore recovery in young adults after stroke
This project will test whether a detailed health and sample-collection approach (deep phenotyping) is practical and acceptable for people aged 18–55 who have had a stroke.
-
Stem cell therapy for chronic stroke recovery
This study is testing whether using a patient's own stem cells can help people with long-term stroke recovery feel better and improve their daily functioning.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Web-based therapy using action observation and mirror therapy for arm weakness after stroke
This trial tests whether a mobile telerehabilitation app delivering action observation therapy (AOT) alone or combined AOT with mirror therapy (AOT-MT) can improve upper limb function in people with subacute stroke.
-
Remote Ischaemic Conditioning for Fatigue After Stroke 2
Aat least 12 weeks after stroke, adults with post-stroke fatigue will try a simple hand-arm cuff treatment at home to see if it helps reduce fatigue.
-
Dual-task balance training plus computer-based cognitive training after stroke
In adults who recently had a stroke, the study tests whether adding computerized cognitive exercises to balance training improves balance and other recovery outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.